Gliknik secures $1.5 million SBIR grant from NCI
November 2011

BALTIMORE, Md.óBiopharmaceutical company Gliknik Inc. recently announced it had been awarded a Small Business Innovation Research Phase II contract for up to $1.5 million from the National Cancer Institute (NCI). Gliknik develops new therapies for patients suffering from cancer and autoimmune/inflammatory diseases, with a specialty in modulation of the immune system. The company has raised $10 million from investors since being formed in 2007, in large part due to Maryland's biotechnology tax credit, and has attracted $2.5 million in nonequity financing from government sources, including the NCI grant. According to David S. Block, Gliknik's CEO, the grant puts Gliknik on a path that could result in clinical trials in two years. The company will use the contract funds to further advance its leads compounds from its stratobody platform toward the clinic.

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.